INTRODUCTION
Fine-needle aspiration of thyroid nodules is becoming more frequent, 1 and often involves aspiration of >1 nodule. 2 Although there is disagreement regarding whether the risk of malignancy is higher in solitary nodules, 3, 4 multiple nodules, 5, 6 or the same, 7 there is a high rate of discordance reported between the histology of multiple nodules, 8 and multiple nodules can be malignant. 9, 10 Some studies have suggested that the risk of malignancy is independent of the number of nodules, 11 whereas others suggest that the dominant nodule is most likely to be malignant 10 and the rate of malignancy may decrease when >2 nodules are present, 7 perhaps because these additional nodules are smaller. 9, 12 As a result, recommendations regarding how many nodules to sample vary, and range from sampling all nodules that meet criteria for aspiration 8 or up to 4 nodules 11 because sampling only 2 nodules may miss approximately 33% to 42% of malignancies. 6, 11 The 2015 American Thyroid Association Management Guidelines for fine-needle aspiration of the thyroid 13 state that "each nodule >1 cm carries an independent risk of malignancy," and suggest that all nodules with sufficiently worrisome clinical characteristics should be biopsied. If a patient has multiple nodules, the sonographic appearance can be used to divide nodules into high-risk, intermediate-risk, low-risk, and very low-risk groups; if none of the nodules has a high or intermediate suspicion of malignancy, then aspiration of the largest nodule is sufficient (recommendation 21C, weak recommendation, low-quality evidence). To further characterize the actual risk of malignancy obtained from biopsies of multiple nodules in clinical practice, we reviewed a large series of thyroid fine-needle aspiration specimens to determine the value of aspirating additional nodules.
MATERIALS AND METHODS
All thyroid fine-needle aspiration specimens that were interpreted at the study institution from January 1997 through June 2016 were reviewed and the results correlated with the results of available histologic follow-up. All cases initially were classified or reclassified (for cases that predated The Bethesda System) according to the most recent Bethesda System for Reporting Thyroid Cytopathology.
14 All cases originally diagnosed as the follicular variant of papillary carcinoma on excision were reviewed and reclassified as a noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) according to recently proposed criteria, 15 provided the tumor met these criteria and only if the entire capsule was submitted (29 cases). If the entire capsule was not submitted, the diagnosis was left as follicular variant of papillary carcinoma. For follow-up, cases with NIFTP were classified as benign. False-negative cases included both sampling (5 cases) and interpretation (5 errors) cases. All aspirates were performed by clinicians. Approximately 25% of fine-needle aspirations were performed in a clinician's office, usually with imaging guidance. Between 2 and 8 passes were made. Approximately 75% of fineneedle aspirations were performed in the radiology department of the study institution with the aid of ultrasound guidance. Only those nodules that met the clinical criteria for biopsy during the time period in which they were aspirated were biopsied. Direct smears were made in all cases, and all were alcohol fixed and stained with either Papanicolaou or hematoxylin and eosin stain. If sufficient material was obtained, cell blocks also were made.
All malignancies at surgical resection were identified. Papillary carcinomas measuring <1 cm that did not correspond to either the clinically identified nodule or the material in the aspirate were determined to be incidental and were not included in the current study.
Statistical Analysis
Statistical analysis was performed using a 2-tailed Student t test or a chi-square test and a threshold of .05 was considered statistically significant.
RESULTS
Patient characteristics are summarized in Table 1 , and tumor characteristics are summarized in Table 2 . There were 12,763 nodules aspirated from 10,506 patients. Patients in whom multiple nodules were aspirated were younger (P<.001) and were more often female (P<.001). Tumors identified in patients who had multiple nodules aspirated were larger (P<.001), were more likely to be Thyroid FNA of Multiple Nodules/Renshaw and Gould
Cancer Cytopathology
November 2017 papillary carcinomas (P<.001), and were less likely to be either follicular or Hurthle cell carcinomas (P 5 .02). The distribution of cytologic diagnoses is shown in Table 3 and the risk of malignancy for each diagnosis is shown in Table 4 . Specimens from patients in whom multiple nodules were aspirated were found to be significantly more likely to be diagnosed as benign (P<.001). The risk of malignancy by diagnosis using either all nodules (Table 4) or by patient (data not shown) did not differ between patients in whom 1 or >1 nodule was aspirated.
For patients in whom >1 nodule was aspirated, the distribution of cytologic diagnoses and risk of malignancy by the number of nodules aspirated is shown in Tables 5 and 6 . There were few significant differences based on the number of nodules that were aspirated. However, the risk of malignancy for a diagnosis of atypical cells of undetermined significance (AUS) in a patient with 3 nodules aspirated was significantly higher than that for a patient in whom 2 nodules were aspirated (47% vs 14%; P 5 .005). When the data were analyzed by the order in which the nodules were aspirated, the data were found to be similar and there were no additional significant differences noted with regard to either cytologic diagnoses or risk of malignancy (data not shown). There were a total of 52 carcinomas, 11 carcinomas, 3 carcinomas, and 0 carcinomas identified in the second, third, fourth, and fifth nodules aspirated. However, of the 3 carcinomas noted in the fourth nodule, all had previously been identified as either positive for malignancy or suspicious for papillary carcinoma on at least 1 of the first 3 nodules aspirated. Both falsenegative cases had 2 nodules sampled. The distribution of carcinomas as detected in patients with >1 biopsy are shown in Table 7 . No new tumors were identified after 3 nodules were biopsied. The worst diagnosis that was detected in each tumor and the nodule number in which it occurred are shown in Table 8 .
Finally, the results of the current study found 12 medullary carcinomas, 11 of which were identified by aspirating a single nodule. The remaining medullary carcinoma represented the first nodule biopsied in a patient in whom 2 nodules were aspirated. There also were 29 cases of NIFTP. All were diagnosed on the dominant nodule.
A total of 25 patients had only a single nodule aspirated, and the NIFTP represented the first nodule biopsied in 4 patients in whom 2 nodules were aspirated.
DISCUSSION
The current study was performed to determine how many nodules need to be biopsied in a patient with multiple thyroid nodules. Currently, there are conflicting data regarding whether these additional nodules have a lower 5, 6 or higher 3,4 rate of malignancy, and whether the risk of malignancy in these additional nodules is independent of the number of nodules (and hence all nodules need to be aspirated) 6, 8, 11, 13 or whether the risk of malignancy declines with additional nodules aspirated and at some point approaches the risk of a benign aspirate. 7, 10 To the best of our knowledge, the current study, which included 63 patients in whom at least 4 nodules were biopsied, is the largest series published to date. The current study data suggest that the risk of each individual nodule is not independent of the other nodules. Having a second suspicious nodule significantly decreases the risk of malignancy of the first nodule (Table 3) , even though the risk of malignancy for any particular cytologic diagnosis remains the same (Table 4) . Because of the decreased incidence of tumors in successively biopsied nodules (Tables 7  and 8 ), only the first 3 nodules needed to be aspirated to detect all carcinomas in the current series. Although additional aspirates did identify malignant nodules, these all were papillary carcinomas that already were identified in the prior 3 biopsies, and the finding of additional foci of papillary carcinoma is neither surprising nor would it affect clinical management.
The data in the literature support this conclusion. One prior study in which 2 patients had >3 nodules were aspirated, 7 also failed to find usefulness in aspirating >3 nodules. A second study with 20 patients in whom at least 4 nodules were biopsied detected 19 of 20 malignancies (95%) by aspirating 3 nodules. 11 Taking these data and the data from the current study together, the risk of malignancy resulting from nodules that are not biopsied when only 3 nodules are biopsied in a patient with 4 nodules is 1.2% (1 of 85 cases), which is the same risk as that for a benign aspirate. Again combining the current study data and those from the literature 11 demonstrates that performing only 2 biopsies would leave the patient with 3 nodules with a risk of malignancy of 5.5% (11 of 200 nodules) from nodules that were not biopsied.
The data from the current study are in keeping with those of other studies in that aspirating only 1 nodule in a patient with >1 suspicious nodule is likely to miss a significant number of carcinomas (25% of the cases in the current series and 33% to 42% of cases in prior series). 6, 11 In the current series, these additional carcinomas all were papillary carcinomas. In contrast, follicular and Hurthle cell carcinomas were more likely to be detected in either single nodules or the dominant nodule in a patient with multiple nodules.
In contrast to other series, we did not observe a trend toward smaller nodules on additional biopsies. 9, 12 However, in the current series, the size of the nodules was calculated only for malignancies and were based on histologic criteria. We did not find the histologic assessment of size to be reliable for tumors other than the dominant nodule.
Other studies used ultrasound findings to determine the size of the nodules and included all nodules regardless of the nature of the nodule. 7, 9, 11, 12 In patients with multiple nodules, the performance of fine-needle aspiration, including the distribution of cytologic diagnoses and the risk of malignancy associated with those diagnoses, usually did not significantly change regardless of the number of nodules aspirated. However, the risk of malignancy for an AUS diagnosis on the third nodule was found to be significantly higher than that for patients in whom only 2 nodules were aspirated. We are not sure of the reason for this. We hypothesize that many of the AUS diagnoses made on third nodules may simply reflect sampling of smaller nodules of papillary carcinoma in patients who already have had a diagnostic aspirate of the first 2 nodules. This difference also may simply reflect a limitation of small sample size for patients with 3 biopsies, resulting in an overestimation of the risk of malignancy, which may not be confirmed with a larger sample. Further study appears warranted. In addition, the malignancies that were detected did change. Not only did the number of carcinomas decrease with the increasing number of nodules biopsied, the malignancies that were detected became exclusively papillary carcinomas, and nearly all of them were assigned diagnoses of either suspicious for malignancy or positive for malignancy. This suggests that although exceptions can occur, there may be an opportunity for cytologists to improve the performance of thyroid fine-needle aspiration by focusing predominantly on identifying features of papillary carcinoma and decreasing the use of indeterminate diagnoses after the first 2 nodules.
To our knowledge, the current study is the first to examine the risk associated with multiple biopsies for NIFTP. The data from the current study clearly demonstrate that this tumor is almost always the dominant nodule and can be identified by aspirating the dominant nodule alone or is likely to be identified on the first of multiple nodules that are biopsied. Thus, one only needs to biopsy the most dominant nodule to identify this tumor. A similar finding was observed for medullary carcinoma.
Original Article
Because the rate of benign diagnoses for aspirates from patients with multiple nodules is significantly higher than that for those in whom only a single nodule is aspirated, the number of nodules aspirated per patient may need to be taken into account when comparing the performance of thyroid fine-needle aspiration between different laboratories. A laboratory that examines more cases with multiple nodules is more likely to have a higher rate of benign cytology and is more likely to have lower indeterminate and malignancy rates than a laboratory that aspirates fewer patients with multiple nodules, regardless of the accuracy of the performance of the test in that laboratory. Quality assessment measures that attempt to account for this difference in population, such as the AUS/malignancy rate, 16 may allow for a more accurate comparison between laboratories that biopsy different numbers of nodules per patient.
There are limitations to the current study. In particular, over the time period of the study, the criteria clinicians use to aspirate nodules changed. To the best of our knowledge, before the most recent American Thyroid Association guidelines of 2016, 13 there was no consensus regarding the ultrasound features of thyroid nodules that were of paramount usefulness for deciding which nodules to aspirate. As a result, clinicians aspirated nodules based on size, microcalcifications, and vascular blood flow. Current criteria are much stricter, and divide patients into lowrisk, intermediate-risk, and high-risk categories. Whether and how the results of the current study would be affected by these changes is not clear. Biopsy of 3 nodules in patients with multiple suspicious nodules lowers the risk of malignancy to that of a benign aspirate. Cytologists can improve the accuracy of their diagnoses by focusing on identifying only cases that are suspicious and positive for papillary carcinoma after the first 2 nodules have been biopsied.
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